NANOLIGENT is awarded for the best company in Health Sciences Price given by the law firm RCD.
The XXIII Investment Forum of ACCIÓ 2018 was celebrated last June 20th with the aim of connecting with the world of private investment. ACCIÓ, Company Competitiveness Agency, had previously published a catalog of startups with the most potential startups in Catalonia, projects selected from more than 100 candidatures were presented for the 2018 Investment Forum of ACTION. The 50 companies in this catalog stand out due to their differential nature and innovative value, due to their social impact and the involvement of the entrepreneurial team. They are companies operating in key sectors for the economy of the future such as life and health sciences, ICT and other crucial cutting-edge technologies for industry 4.0 including 3D printing, IoT and virtual reality. The 21 finalists had the opportunity to present themselves to a large number of investors and venture capital funds during the Forum’s celebration, an audience of 600 people who voted the 9 best companies to participate in the final. Nanoligent, S.L., the company stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from NANBIOSIS Unit 1, professor Dr. M. Mangués from NANBIOSIS Unit 18, and entrepreneur Dr. M. Rodríguez won the award for the best company in Health Sciences given by the law firm RCD (Rousaud Costas Duran)
NANOLIGENT’s mission is to improve the lives of patients by designing new medications that selectively target the cells affected by disease. With this approach NANOLIGENT develops treatments that are more effective and have less adverse effects than classical drugs using state-of-the-art protein engineering and nanobiotechnology. Currently Nanoligent is working on antimetastatic medication for colorectal cancer and its business model is carrying out a first clinical trial which demonstrates the efficacy of the medication in humans and allows the company to sign a license agreement with a pharmaceutical company